Francis Knuettel II - 22 May 2026 Form 4 Insider Report for Pelthos Therapeutics Inc. (PTHS)

Reporting relationship: CFO, Treas & Secty
Issuer ticker: PTHS
Reported as of: 22 May 2026
Net transaction value: -$40,265
SEC form: 4
Accepted by SEC: 26 May 2026, 19:17:24 UTC
Prior SEC filing: 30 Apr 2026
Next SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Francis Knuettel II

Key filing fact

Francis Knuettel II filed Form 4 for Pelthos Therapeutics Inc. (PTHS) on 26 May 2026.

Key facts

This page summarizes Francis Knuettel II's Form 4 filing for Pelthos Therapeutics Inc. (PTHS).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 26 May 2026, 19:17.

Change

Previous filing in this sequence was filed on 30 Apr 2026.
Current net transaction value: -$40,265.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001433316 Primary reporting owner

Francis Knuettel II

Relationship: CFO, Treas & Secty
Address: C/O PELTHOS THERAPEUTICS INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM
Signature: /s/ Francis Knuettel II
Signature date: 26 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PTHS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -13,947
Change %: -42%
Price: $0.000000^*
Shares after: 19,525
Date: 22 May 2026
Ownership: Direct
Footnotes: F1, F2

PTHS transaction

Common Stock

Sale

Transaction value: $40,265
Shares: -1,500
Change %: -12%
Price: $26.84
Shares after: 11,316
Date: 22 May 2026
Ownership: By Lara Knuettel Revocable Trust
Footnotes: F3, F4

PTHS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 10,000
Date: 22 May 2026
Ownership: By Camden Capital LLC
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTHS transaction Derivative

Stock Option

Award

Transaction value
Shares: +59,500
Change %
Price
Shares after: 59,500
Date: 22 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 59,500
Exercise price: $13.50
Footnotes: F5

PTHS transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares: -42,500
Change %: -100%
Price
Shares after: 0
Date: 22 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 42,500
Exercise price: $13.50
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Francis Knuettel II is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

Represents the forfeiture and cancellation of unvested restricted stock units ("RSUs") of Pelthos Therapeutics Inc. (the "Issuer"), for no consideration pursuant to that certain Separation Agreement entered into on May 15, 2026 (the "Separation Agreement") in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

Footnote F2

The Separation Agreement provides for the acceleration of vesting of 19,525 RSUs out of the 33,472 previously reported RSUs granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of common stock, par value, $0.0001 per share ("Common Stock"), subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The 19,525 unvested RSUs became fully vested on May 22, 2026 upon expiration of the revocation period in the Separation Agreement. The transaction is exempt under Rule 16b-3(d). The acceleration does not represent a new grant of RSUs.

Footnote F3

Represents an open market sale of the Lara Knuettel Revocable (the "Trust") on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $26.66 to $27.16. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected

Footnote F4

Francis Knuettel II is the co-trustee of the Trust and manager of Camden Capital LLC ("Camden"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Footnote F5

Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer. The unvested stock options became fully vested and exercisable on May 22, 2026. The transaction is exempt under Rule 16b-3(d). This acceleration does not represent a new grant of options. The stock options may be exercised only until January 15, 2027, subject to the terms of the 2023 Plan and the Separation Agreement.

Footnote F6

Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.